- Glow LifeTech (GLOW) is co-sponsoring a clinical study to assess the impact of Artemic Support® in patients with long COVID syndrome
- Long Covid is estimated to affect approximately 10-35 per cent of all COVID patients
- Artemic Support is a natural health product made from curcumin, boswellia and vitamin C designed to reduce inflammation
- The study is being executed in collaboration with Swiss PharmaCan, the sponsor of the study
- The study is expected to be completed by February 2022, with results published in Q2 of 2022
- Glow LifeTech is a biotechnology company focused on producing nutraceutical and cannabinoid-based products
- Glow LifeTech Corp. (GLOW) opened trading at C$0.27 per share
Glow LifeTech (GLOW) is co-sponsoring a clinical study to assess the impact of Artemic Support® in patients with long COVID syndrome.
Post-acute COVID syndrome (PACS) or “long COVID” presents itself as a wide range of ongoing symptoms for several weeks after first being infected with SARS-COV-2. Long Covid is estimated to affect approximately 10-35 per cent of all COVID patients. Reducing inflammation associated with the condition could improve patient outcomes.
Artemic Support is a natural health product made from curcumin, boswellia and vitamin C designed to reduce inflammation and is formulated with MyCell Technology ingredients to deliver faster, more effective cellular absorption of natural active ingredients.
This new innovation is the second product in the company’s artemic product range to progress to the clinical trial phase to determine safety and efficacy against SARS2-COV-2 related diseases. In April 2020, the company submitted its first product, Artemic™ Rescue, to Health Canada as a Natural Health Product following successful results from a Phase II Clinical Trial with patients diagnosed with moderate COVID-19.
The study is being executed in collaboration with Swiss PharmaCan, the sponsor of the study and Glow as the co-sponsor in addition to MGC Pharmaceuticals. The study will include 150 patients suffering from post-acute COVID syndrome (PACS) and will be administered by UniversalDoctors across 3 primary care centers in Catalonia, Spain. Patients will take Artemic Support® for 6 weeks under the supervision of their doctor, and their progress will be measured throughout the period to determine if symptoms are reduced while monitoring for adverse events.
Ethics Committee approval has been obtained and the study is already underway with 50 patients enrolled. The study is expected to be completed by February 2022, with results published in Q2 of 2022.
Study organizer, Dr. Dieter L. Russmann MD, Senator h.c., from Swiss PharmaCan commented on the study.
“I’m excited about the “First Patient In” on December 13, as I’m expecting highly valuable results on the safety and efficacy of Artemic Support®, based on its breakthrough MyCell technology, and the potential benefit for millions of people suffering from Long COVID, who have had no therapeutic options so far.”
Clark Kent, CEO Glow LifeTech added,
“Scientific validation and research is paramount to the ongoing commercial efforts of MyCell® technology. Glow is pleased to be included in important work to support Long COVID symptoms, and affirm the potential health benefits of its leading-edge ingredients with our partners.”
MyCell Technology is Glow’s proprietary naturally derived delivery system which improves the absorption and effectiveness of natural active compounds including cannabinoids, vitamins, botanicals and more. MyCell enhanced concentrates allow them to power a variety of product formats including droppers, beverages, foods, topicals, and capsules.
Glow LifeTech is a biotechnology company focused on producing nutraceutical and cannabinoid-based products with dramatically enhanced bioavailability, absorption and effectiveness.
Glow LifeTech Corp. (GLOW) opened trading at C$0.27 per share.
